Hemp industry turns to Pharma tech to meet growing demand for Cannabidiol

Hemp industry turns to Pharma tech to meet growing demand for Cannabidiol

Rhizo Sciences partners with Thar Process to extract CBD from hemp at industrial scale


Seattle, May 10, 2018


The hemp industry is undergoing a renaissance due to an explosion of interest in Cannabidiol, (aka CBD) but it’s struggling to keep up with demand for quality product. Manufacturers are now turning to the pharmaceutical industry for proven processing technology.


Rhizo Sciences, a US based medical cannabis company has announced plans to partner with leading pharma grade Supercritical CO2 extraction and chromatography firm Thar Process.


Under the collaboration, Rhizo Sciences and Thar Process will work together to develop the next generation of hemp extraction machines – large scale systems able to process hundreds or thousands of kg of cannabis or hemp biomass daily.


Rhizo Sciences approached Thar because of their expertise building large scale GMP and food grade pharmaceutical extraction facilities. The booming hemp industry in the USA has a growing need for hemp processing facilities to of isolate CBD from hemp.


The hemp industry in North America is booming due to rising demand for Cannabidiol, or CBD, the most prominent medicinal compound in hemp. CBD is non-intoxicating and has powerful therapeutic effects as an antiinflammatory, analgesic and anti-seizure medicine.


The FDA recently granted pre-approval to a CBD-based anti-epilepsy drug Epidolex to GW Pharma – a UK pharmaceutical company. The move represents the first approval of a cannabis-derived drug in North America and represents a major milestone in the cannabis-derived pharmaceutical industry.


Dozens of other companies currently have cannabinoid products undergoing clinical trials, and CBD is widely used as a novel food product and ingredient in the nutraceutical industry.

The World Health Organisation (WHO) has published a report that states naturally occurring CBD is safe and well tolerated in humans (and animals), and is not associated with any negative public health effects [PDF].


The result is an explosion in demand for food grade and pharmaceutical grade CBD for everything from anti epilepsy medications to cosmetics, coffee and supplements, but a severe shortage of supply of good grade or pharma grade product.

“We have enormous interest from buyers for CBD oils, extracts and isolate because most of the product on the market is of low purity, has questionable provenance and doesn’t meet basic quality standards.” said Dallas McMillan, President of Rhizo Sciences. “Manufacturers need food grade or pharma grade GMP Cannabidiol, but it’s in scarce supply worldwide. We’ve been approached by farmers growing thousands of acres of hemp but they can’t sell it or process it all themselves. We’re working to help them bridge that gap.”


Rhizo Sciences will work with Thar Process to develop large scale facilities to produce GMP food grade oils and extracts, as well as pharmaceutical grade 99.9% pure cannabinoids for the biotechnology and pharmaceutical industries.


“Thar Process has been developing the technology used in the hemp industry for decades. We’ve also build large specialized GMP pharmaceutical manufacturing plants and industrial scale food oil processing facilities, so we’re perfectly positioned to help scale the medical hemp industry.” said Todd Palcic, President of Thar Process.


The CBD industry is at a critical stage where the raw material supply is there but the quality assurance and distribution pathways aren’t. Many mainstream businesses want to introduce CBD product lines, but right now they can’t because the product available doesn’t meet basic consumer safety standards.


Most hemp processors currently run small systems and use toxic or explosive solvents to extract and purify CBD. These systems are cheap to set up, but have high operating costs and face problems with safety and yield as they scale from hundreds to thousands of pounds of hemp per day. New technology and manufacturing standards are needed before mainstream manufacturers can safely offer CBD products.


“Rhizo Sciences was looking for a food grade solution that could meet GMP and ISO standards for international export, and could easily scale to produce thousands or 10,000s kg of CBD per month, while minimising waste. Supercritical CO2 is the ideal solution because it lets us extract and isolate individual cannabinoids to a pharmaceutical level of purity without toxic solvents.”

Under the agreement Thar Process and Rhizo Sciences will develop GMP processing systems or farmers and investors. The CBD oil and Active Pharmaceutical Ingredients (APIs) will be sold to manufacturers of CBD-infused products including foods beverages, supplements and cosmetics as well as more familiar medical products such as tablets and tinctures.


The world CBD market is projected to reach $2 Billion by 2021, and US hemp production has grown 140% from 2016 to 2017. Hemp is currently legal to grow in 10 US states, and recent legislation from introduced into the Senate by Mitch McConnell aims to legalize hemp as a commodity crop, which would further boost investment in the sector. CBD may be the high value product that helps the hemp industry finally go mainstream as an agricultural crop.


About Rhizo Sciences

Rhizo Sciences is a Seattle, Washington based privately held cannabis and hemp company that develops and manages cGMP export processing facilities internationally. In the US, they focus on large scale hemp processing facilities. The company manages supply chains to ensure legal, compliant, quality production of CBD and cannabis products internationally.


The company offers manufacturing and distribution capability to legal CBD and medical cannabis markets. The firm provides in supplying food grade oils and Active Pharmaceutical Ingredients (APIs) to cannabis brands and pharmaceutical manufacturers.


Learn more at www.rhizosciences.com


About Thar Process

Thar Process, Inc. seeks to be the global leader in supercritical fluid technology and equipment by providing solutions involving chemistry, design, and process development and optimization from concept through commercialization. With our proprietary technology, R&D and toll processing services complementing our expertise in bench to production-scale equipment, Thar Process is the only single-point-of-access provider of supercritical fluid technology solutions worldwide.
Thar Process has developed processes and equipment technologies for the pharmaceutical, food, nutraceutical, chemical and electronic industries.


Learn more at www.tharprocess.com


For all enquiries contact Rhizo Sciences at the details below.


Press Contact

Name: Dallas McMillan

Company: Rhizo Sciences

Phone: +1 (206) 452-3348

Email: dallas@rhizosciences.com

Website: www.rhizosciences.com

Press Kit: www.rhizosciences.com/cannabis-hemp-cbd-solutions/



By |2018-05-11T03:34:15+00:00May,18 11|Categories: Medical Cannabis|0 Comments

About the Author:

Dallas McMillan is founder and President of Rhizo Sciences and leads the international hemp and cannabis activities. Recognised as a leading authority in production of truly medical grade cannabis, Dallas leads a team of agricultural, medical and pharmaceutical specialists with a passion for cannabis and hemp and the impact they can make on human health, the environment, and economies. Key to Rhizo Sciences' success in the industry has been an emphasis on leveraging proven technology, personnel and processes from traditional industries while honoring the unique value and characteristics of the cannabis plant and those who have worked tirelessly to bring it into the mainstream. Connect with Dallas on Linkedin or Email.

Leave A Comment